Author
Mark C. Petrie
Other affiliations: Robertson Centre for Biostatistics, Jubilee Hospital, British Heart Foundation ...read more
Bio: Mark C. Petrie is an academic researcher from University of Glasgow. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 64, co-authored 293 publications receiving 30430 citations. Previous affiliations of Mark C. Petrie include Robertson Centre for Biostatistics & Jubilee Hospital.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
13,400 citations
••
TL;DR: This paper presents a Randomized Assessment of Acute Coronary Syndrome Treatment of Intracoronary Stenting With Antithrombotic Regimen and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction.
Abstract: ABOARD
: Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention
ACC
: American College of Cardiology
ACE
: angiotensin-converting enzyme
ACS
: acute coronary syndromes
ACT
: activated clotting time
ACUITY
: Acute Catheterization and Urgent Intervention Triage strategY
AF
: atrial fibrillation
AHA
: American Heart Association
APPRAISE
: Apixaban for Prevention of Acute Ischemic Events
aPTT
: activated partial thromboplastin time
ARB
: angiotensin receptor blocker
ARC
: Academic Research Consortium
ATLAS
: Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome
BARI-2D
: Bypass Angioplasty Revascularization Investigation 2 Diabetes
BMS
: bare-metal stent
BNP
: brain natriuretic peptide
CABG
: coronary bypass graft
CAD
: coronary artery disease
CI
: confidence interval
CK
: creatinine kinase
CKD
: chronic kidney disease
CK-MB
: creatinine kinase myocardial band
COX
: cyclo-oxygenase
CMR
: cardiac magnetic resonance
COMMIT
: Clopidogrel and Metoprolol in Myocardial Infarction Trial
CPG
: Committee for Practice Guidelines
CrCl
: creatinine clearance
CRP
: C-reactive protein
CRUSADE
: Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines
CT
: computed tomography
CURE
: Clopidogrel in Unstable Angina to Prevent Recurrent Events
CURRENT
: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events
CYP
: cytochrome P450
DAPT
: dual (oral) antiplatelet therapy
DAVIT
: Danish Study Group on Verapamil in Myocardial Infarction Trial
DES
: drug-eluting stent
DTI
: direct thrombin inhibitor
DIGAMI
: Diabetes, Insulin Glucose Infusion in Acute Myocardial Infarction
EARLY-ACS
: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome
ECG
: electrocardiogram
eGFR
: estimated glomerular filtration rate
ELISA
: Early or Late Intervention in unStable Angina
ESC
: European Society of Cardiology
Factor Xa
: activated factor X
FFR
: fractional flow reserve
FRISC
: Fragmin during Instability in Coronary Artery Disease
GP IIb/IIIa
: glycoprotein IIb/IIIa
GRACE
: Global Registry of Acute Coronary Events
HINT
: Holland Interuniversity Nifedipine/Metoprolol Trial
HIT
: heparin-induced thrombocytopenia
HORIZONS
: Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction
HR
: hazard ratio
hsCRP
: high-sensitivity C-reactive protein
ICTUS
: Invasive vs. Conservative Treatment in Unstable coronary Syndromes
INR
: international normalized ratio
INTERACT
: Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment
ISAR-COOL
: Intracoronary Stenting With Antithrombotic Regimen Cooling Off
ISAR-REACT
: Intracoronary stenting and Antithrombotic Regimen- Rapid Early Action for Coronary Treatment
i.v.
: intravenous
LDL-C
: low-density lipoprotein cholesterol
LMWH
: low molecular weight heparin
LV
: left ventricular
LVEF
: left ventricular ejection fraction
MB
: myocardial band
MDRD
: Modification of Diet in Renal Disease
MERLIN
: Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes
MI
: myocardial infarction
MINAP
: Myocardial Infarction National Audit Project
MRI
: magnetic resonance imaging
NNT
: numbers needed to treat
NSAID
: non-steroidal anti-inflammatory drug
NSTE-ACS
: non-ST-elevation acute coronary syndromes
NSTEMI
: non-ST-elevation myocardial infarction
NT-proBNP
: N-terminal prohormone brain natriuretic peptide
OASIS
: Organization to Assess Strategies for Ischaemic Syndromes
OPTIMA
: Optimal Timing of PCI in Unstable Angina
OR
: odds ratio
PCI
: percutaneous coronary intervention
PENTUA
: Pentasaccharide in Unstable Angina
PLATO
: PLATelet inhibition and patient Outcomes
PURSUIT
: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
RCT
: randomized controlled trial
RE-DEEM
: Randomized Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes (ACS) Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin And Clopidogrel
REPLACE-2
: Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events
RIKS-HIA
: Register of Information and Knowledge about Swedish Heart Intensive care Admissions
RITA
: Research Group in Instability in Coronary Artery Disease trial
RR
: relative risk
RRR
: relative risk reduction
STE-ACS
: ST-elevation acute coronary syndrome
STEMI
: ST-elevation myocardial infarction
SYNERGY
: Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trial
SYNTAX
: SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
TACTICS
: Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy
TARGET
: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial
TIMACS
: Timing of Intervention in Patients with Acute Coronary Syndromes
TIMI
: Thrombolysis In Myocardial Infarction
TRITON
: TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction
UFH
: unfractionated heparin
VKA
: vitamin K antagonist
VTE
: venous thrombo-embolism
Guidelines summarize and evaluate all available evidence, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes but are complements for textbooks and cover the European Society of Cardiology (ESC) Core Curriculum topics. Guidelines and recommendations should help the physicians to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible physician(s).
A great number of Guidelines have been issued in recent years by the ESC as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for diagnosis, management, and/or prevention of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of recommendation of particular treatment options were weighed and graded according to pre-defined scales, as outlined in Tables 1 and 2 . …
3,841 citations
••
University of Glasgow1, Brigham and Women's Hospital2, Yale University3, University of Copenhagen4, University of Missouri–Kansas City5, National University of Cordoba6, Wrocław Medical University7, Harvard University8, University of Minnesota9, Charles University in Prague10, Saarland University11, Taipei Veterans General Hospital12, National Yang-Ming University13, Slovak Medical University14, Fudan University15, Libin Cardiovascular Institute of Alberta16, University of Calgary17, Sofia Medical University18, University of Gothenburg19, Semmelweis University20, University of São Paulo21, Montreal Heart Institute22, University of Toronto23, Uppsala University24, University of Wisconsin-Madison25, AstraZeneca26
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Abstract: Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-ind...
3,541 citations
••
TL;DR: In this randomized trial, patients assigned to CABG, as compared with those assigned to medical therapy alone, had lower rates of death from cardiovascular causes and ofdeath from any cause or hospitalization for cardiovascular causes.
Abstract: The primary outcome occurred in 244 patients (41%) in the medical-therapy group and 218 (36%) in the CABG group (hazard ratio with CABG, 0.86; 95% confidence interval [CI], 0.72 to 1.04; P = 0.12). A total of 201 patients (33%) in the medicaltherapy group and 168 (28%) in the CABG group died from an adjudicated cardiovascular cause (hazard ratio with CABG, 0.81; 95% CI, 0.66 to 1.00; P = 0.05). Death from any cause or hospitalization for cardiovascular causes occurred in 411 patients (68%) in the medical-therapy group and 351 (58%) in the CABG group (hazard ratio with CABG, 0.74; 95% CI, 0.64 to 0.85; P<0.001). By the end of the followup period (median, 56 months), 100 patients in the medical-therapy group (17%) underwent CABG, and 555 patients in the CABG group (91%) underwent CABG. Conclusions In this randomized trial, there was no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary end point of death from any cause. Patients assigned to CABG, as compared with those assigned to medical therapy alone, had lower rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; STICH ClinicalTrials.gov number, NCT00023595.)
930 citations
••
TL;DR: Overall, GLP-1 receptor agonist treatment reduced MACE by 12% and there was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer.
854 citations
Cited by
More filters
••
University of Manchester1, University of Barcelona2, St George's Hospital3, University of Marburg4, University of Texas Health Science Center at San Antonio5, Imperial College London6, University of Modena and Reggio Emilia7, University of Michigan8, Hokkaido University9, University of British Columbia10
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Abstract: Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization. Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials. In 1998, in an effort to bring more attention to COPD, its management, and its prevention, a committed group of scientists encouraged the U.S. National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Among the important objectives of GOLD are to increase awareness of COPD and to help the millions of people who suffer from this disease and die prematurely of it or its complications. The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, published in 2001. The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared. GOLD national leaders, a network of international experts, have initiated investigations of the causes and prevalence of COPD in their countries, and developed innovative approaches for the dissemination and implementation of COPD management guidelines. We appreciate the enormous amount of work the GOLD national leaders have done on behalf of their patients with COPD. Despite the achievements in the 5 years since the GOLD report was originally published, considerable additional work is ahead of us if we are to control this major public health problem. The GOLD initiative will continue to bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary.
17,023 citations
••
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
13,400 citations
••
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
11,386 citations
01 Jan 2014
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Abstract: XI. STRATEGIES FOR IMPROVING DIABETES CARE D iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes. These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed.): Medical Management of Type 1 Diabetes (1), Burant (Ed): Medical Management of Type 2 Diabetes (2), and Klingensmith (Ed): Intensive Diabetes Management (3). The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.
9,618 citations
••
TL;DR: The once-in-a-lifetime treatment with Abciximab Intracoronary for acute coronary syndrome and a second dose intravenously for atrial fibrillation is recommended for adults with high blood pressure.
Abstract: ACE
: angiotensin-converting enzyme
ACS
: acute coronary syndrome
ADP
: adenosine diphosphate
AF
: atrial fibrillation
AMI
: acute myocardial infarction
AV
: atrioventricular
AIDA-4
: Abciximab Intracoronary vs. intravenously Drug Application
APACHE II
: Acute Physiology Aand Chronic
7,519 citations